Citation APA
Saura, C., Hlauschek, D., Oliveira, M., Zardavas, D., Jallitsch-Halper, A., de la Peña, L., Nuciforo, P. G., Ballestrero, A., Dubsky, P., Lombard, J. J., Vuylsteke, P., Castaneda, C. A., Colleoni, M. A., Santos Borges, G., Ciruelos, E., Fornier, M., Boer, K., Bardia, A., Wilson, T. R., Stout, T. T., Hsu, J. J., Shi, Y., Piccart-Gebhart, M., Gnant, M., Baselga, J., & de Azambuja, E. (2019). Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet oncology, 20(9), 1226-1238. doi:10.1016/S1470-2045(19)30334-1
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/296670